Sarepta Therapeutics, Inc.
Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA
Last updated:
Abstract:
Provided are methods of treatment in subjects having progeroid diseases and related conditions which rely upon LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.
Status:
Grant
Type:
Utility
Filling date:
6 Oct 2017
Issue date:
3 Sep 2019